

PATENT  
454313-2340.2AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter and without intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS

61  
1. (Currently amended) A composition for reducing viral load of porcine circovirus-2 (PCV-2) in a pig comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes PCV-2 ORF4, ~~PCV-2 ORF13~~, or PCV-2 ORF 4 and ORF13.

~~2/10~~ (Previously amended) The composition of claim 1, wherein the vector contains and expresses PCV-2 ORF4 and ORF13.

~~3-16~~. (Cancelled)

~~17~~. (Previously amended) The composition of claim 1, wherein the vector comprises a DNA vector plasmid, an *E. coli* cell, a baculovirus, a pig herpes virus, including Aujeszky's disease virus, a porcine adenovirus, or a poxvirus, including a vaccinia virus, an avipox virus, a canarypox virus, or a swinepox virus.

~~3/18~~. (Previously amended) The composition of claim ~~17~~ wherein the vector is a DNA vector.

~~4/19~~. (Previously amended) The composition of claim ~~17~~ wherein the vector is a canarypox virus.

~~20~~. (Cancelled)

~~5/21~~. (Previously amended) The composition of claim 1, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector expressing the immunogen can also be the vector expressing PCV-2 ORF.

~~22~~. (Cancelled)

~~23~~. (Original) The composition of claim ~~21~~ wherein the at least one additional pig pathogen is selected from the group consisting of PRRS, *Mycoplasma hyopneumoniae*, *Actinobacillus pleuropneumoniae*, *E. coli*, Atrophic Rhinitis, Pseudorabies, Hog cholera, Swine Influenza, encephalomyocarditis virus, and PPV.

67

6

PATENT  
454313-2340.2

12  
24. (Previously amended) The composition of claim 1, wherein the vector contains and expresses PCV-2 ORF4.

25-30. (Cancelled)

31. 7 (Previously amended) A method for reducing viral load of porcine circovirus-2 (PCV-2) in a pig comprising inducing an immunological or immunogenic response against PCV-2 in the pig comprising administering to the pig the composition of claim 1.

32. 11 (Previously amended) A method for reducing viral load of PCV-2 in a pig comprising inducing an immunological or immunogenic response against PCV-2 in the pig comprising administering to the pig the composition of claim 1.

33-42. (Cancelled)

43. 12 (Previously amended) The method of claims 31, 32, 54 or 55, wherein the composition additionally includes at least one immunogen from at least one additional pig pathogen or a vector expressing such an immunogen.

44. 16 (Previously amended) The method of claim 43 wherein the composition additionally includes at least one immunogen from at least one additional pig pathogen.

45. 17 (Original) The method of claim 43 wherein the at least one additional pig pathogen is selected from the group consisting of PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, *E. coli*, Atrophic Rhinitis, Pseudorabies, Hog cholera, Swine Influenza, encephalomyocarditis virus, and PPV.

46. 18 (Previously amended) The method of claim 45, wherein the at least one additional pig pathogen is porcine parvovirus (PPV).

47. 19 (Currently amended) The method of claims 32, 33, 54 or 55, wherein the vector comprises a DNA plasmid, an *E. coli* cell, a baculovirus, a pig herpes virus, Aujeszky's disease virus, a porcine adenovirus, or a poxvirus.

48. 19 (Currently amended) The method of claim 47, wherein the vector is a DNA plasmid, vector.

49. 20 (Previously amended) The method of claim 47, wherein the vector is a canarypox virus.

50. 8 (Currently amended) The method of claim 31, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector expressing the immunogen can also be the vector expressing PCV-2 ORF4, ~~PCV-2 ORF13~~, or PCV-2 ORF 4 and ORF13.

PATENT  
454313-2340.2

51. (Cancelled)

52. (Original) The method of claim 50 wherein the at least one additional pig pathogen is selected from the group consisting of PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, E. coli, Atrophic Rhinitis, Pseudorabies, Hog cholera, Swine Influenza, encephalomyocarditis virus, and PPV.

53. (Cancelled)

54. (Previously amended) A method of reducing viral load of PCV-2 in a pig comprising inducing an immunological or immunogenic response again PCV-2 in the pig comprising administering to the pig the composition of claim 24.

55. (Currently amended) A method of reducing viral load of PCV-2 in a pig comprising inducing an immunological or immunogenic response again PCV-2 in the pig comprising administering to the pig an effective amount of a composition for reducing viral load of PCV-2 in a pig comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes PCV-2 ORF13, the composition of claim 25.

56-61. (Cancelled)

62. (Previously amended) The method of claims 31, 32, 54 or 55, wherein the administering is prior to breeding.

63. (Previously amended) The method of claims 31, 32, 54 or 55, wherein the pig is a pregnant female pig.

64-107. (Cancelled)